$EQ News

Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504

Equillium Doses First Patient In Australia In Its Phase 1 Clinical Study Of EQ504 To Treat Serious Inflammatory Diseases

Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6

Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference

Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504

Equillium Announces Poster Presentations at the 7th International AHR Conference

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

EQ Inc. Reports Second Quarter 2026 Financial Results

Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Equillium: The Market Seems To Have Already Priced In Phase 1 Success

Integrated Rewards Expands Offer Network into Everyday Spend Categories Like Fuel, Hotel and Grocery

Piper Sandler Initiates Coverage On Equillium with Overweight Rating, Announces Price Target of $20

Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504

EQ Works Expands ClearLake Platform with AI-Powered Audience Segments

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease - Slideshow

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target

Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Disease Transcript